Keywords: Eisai, Halaven, UK, NICE, Cost effectiveness

UK’s NICE rejects Eisai’s Halaven for advanced breast cancer

Article | 17 November 2011

Print This

In a second negative from the UK’s National Institute for Health and Clinical Excellence, in final draft guidance ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in